M
ME NEWS
13 May 2025, 19:35
Biogen Issues $1.75 Billion in Senior Notes to Refinance 2025 Debt
Biogen Inc. has completed a $1.75 billion offering of senior unsecured notes, consisting of $400 million in 5.050% notes due 2031, $650 million in 5.750% notes due 2035, and $700 million in 6.450% notes due 2055. The issuance was managed by BofA Securities, Citigroup, and J.P. Morgan as lead underwriters.
Proceeds from the sale will be used to retire Biogen’s outstanding 4.050% senior notes maturing in 2025, which carry the same principal amount. Any remaining funds will be directed toward general corporate purposes and working capital.
The new notes are callable at the company’s discretion and include provisions for repurchase at 101% of par in the event of a qualifying change in control. The issuance strengthens Biogen’s debt profile by locking in longer-term financing while providing flexibility for future operations.
Biogen Inc. has completed a $1.75 billion offering of senior unsecured notes, consisting of $400 million in 5.050% notes due 2031, $650 million in 5.750% notes due 2035, and $700 million in 6.450% notes due 2055. The issuance was managed by BofA Securities, Citigroup, and J.P. Morgan as lead underwriters.
Proceeds from the sale will be used to retire Biogen’s outstanding 4.050% senior notes maturing in 2025, which carry the same principal amount. Any remaining funds will be directed toward general corporate purposes and working capital.
The new notes are callable at the company’s discretion and include provisions for repurchase at 101% of par in the event of a qualifying change in control. The issuance strengthens Biogen’s debt profile by locking in longer-term financing while providing flexibility for future operations.
